Name | 3,4-DIHYDROXYBENZYLAMINE HYDROBROMIDE |
Synonyms | DHBA DHBA HYDROBROMIDE 4-(aminomethyl)benzene-1,2-diol (3,4-dihydroxyphenyl)methanaminium 4-(AMINOMETHYL)CATECHOL HYDROBROMIDE 3,4-DIHYDROXYBENZYLAMINE HYDROBROMIDE 4-(aminomethyl)pyrocatechol hydrobromide 3,4-Dihydroxybenzylamine·hydrogen bromide 4-(Aminomethyl)catechol hydrobromide, DHBA hydrobromide 4-(Aminomethyl)catechol hydrobromide, DHBA hydrobromide |
CAS | 16290-26-9 |
EINECS | 240-382-8 |
InChI | InChI=1/C7H9NO2.BrH/c8-4-5-1-2-6(9)7(10)3-5;/h1-3,9-10H,4,8H2;1H |
Molecular Formula | C7H10BrNO2 |
Molar Mass | 220.06 |
Melting Point | 184-186°C(lit.) |
Boling Point | 357.4°C at 760 mmHg |
Flash Point | 170°C |
Vapor Presure | 1.32E-05mmHg at 25°C |
Appearance | Crystalline Powder |
Color | Light beige |
BRN | 4002646 |
Storage Condition | Inert atmosphere,Room Temperature |
Sensitive | Hygroscopic |
Physical and Chemical Properties | Sensitivity: hydrogen WGK Germany:3 |
Hazard Symbols | Xi - Irritant![]() |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
WGK Germany | 3 |
FLUKA BRAND F CODES | 10 |
HS Code | 29222900 |
biological activity | 3,4-Dihydroxybenzylamine hydrate (NSC 263475 hydrate) is a structurally modified dopamine analog cytotoxicant, inhibits DNA polymerase activity in melanoma cells. 3,4-Dihydroxybenzylamine hydrochloride showed different growth inhibitory activity in melanoma cell lines with different degrees of tyrosinase activity. |
Cell Line: | Human and Murine Melanoma Cell Lines; Non-Melanoma Cell Lines |
Concentration: | 1 μM-10 mM |
Incubation Time: | 48 hours |
Result: | Inhibited melanoma cell Lines growth. Exhibited increased life-span of 44%,46%, 70% and 50% for 200 mg/kg, 400 mg/kg, 600 mg/kg, and 800 mg/kg, respectively. |
Animal Model: | C57BL/6 mice with B6D2F1 cells |
Dosage: | 200 mg/kg, 400 mg/kg, 600 mg/kg, and 800 mg/kg |
Administration: | Intraperitoneal injection |